company background image
PROC

Procaps GroupNasdaqGM:PROC Stock Report

Last Price

US$9.13

Market Cap

US$1.0b

7D

-0.2%

1Y

-10.8%

Updated

23 Jan, 2022

Data

Company Financials +
PROC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

PROC Stock Overview

Procaps Group, S.A. operates as an integrated healthcare and pharmaceutical company worldwide.

Procaps Group Competitors

Johnson & Johnson

NYSE:JNJ

US$434.0b

Pfizer

NYSE:PFE

US$296.3b

Merck

NYSE:MRK

US$202.0b

Catalent

NYSE:CTLT

US$17.5b

Price History & Performance

Summary of all time highs, changes and price drops for Procaps Group
Historical stock prices
Current Share PriceUS$9.13
52 Week HighUS$11.98
52 Week LowUS$7.99
Beta0.060
1 Month Change-4.70%
3 Month Change-6.55%
1 Year Change-10.75%
3 Year Changen/a
5 Year Changen/a
Change since IPO-7.22%

Recent News & Updates

Jan 10
Calculating The Fair Value Of Procaps Group, S.A. (NASDAQ:PROC)

Calculating The Fair Value Of Procaps Group, S.A. (NASDAQ:PROC)

Does the January share price for Procaps Group, S.A. ( NASDAQ:PROC ) reflect what it's really worth? Today, we will...

Shareholder Returns

PROCUS PharmaceuticalsUS Market
7D-0.2%-2.5%-6.1%
1Y-10.8%5.3%4.2%

Return vs Industry: PROC underperformed the US Pharmaceuticals industry which returned 5.3% over the past year.

Return vs Market: PROC underperformed the US Market which returned 4.2% over the past year.

Price Volatility

Is PROC's price volatile compared to industry and market?
PROC volatility
PROC Average Weekly Movement7.5%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: PROC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: PROC's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19774,500Ruben Minskihttps://www.procapsgroup.com

Procaps Group, S.A. operates as an integrated healthcare and pharmaceutical company worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products.

Procaps Group Fundamentals Summary

How do Procaps Group's earnings and revenue compare to its market cap?
PROC fundamental statistics
Market CapUS$1.03b
Earnings (TTM)-US$45.12m
Revenue (TTM)US$401.35m

2.6x

P/S Ratio

-22.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PROC income statement (TTM)
RevenueUS$401.35m
Cost of RevenueUS$173.17m
Gross ProfitUS$228.18m
ExpensesUS$273.31m
Earnings-US$45.12m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.40
Gross Margin56.85%
Net Profit Margin-11.24%
Debt/Equity Ratio602.2%

How did PROC perform over the long term?

See historical performance and comparison

Valuation

Is Procaps Group undervalued compared to its fair value and its price relative to the market?

2.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PROC ($9.13) is trading below our estimate of fair value ($9.35)

Significantly Below Fair Value: PROC is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: PROC is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: PROC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PROC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PROC is overvalued based on its PB Ratio (29.3x) compared to the US Pharmaceuticals industry average (2.1x).


Future Growth

How is Procaps Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

106.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PROC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: PROC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PROC's is expected to become profitable in the next 3 years.

Revenue vs Market: PROC's revenue (11.6% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: PROC's revenue (11.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PROC's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Procaps Group performed over the past 5 years?

-273.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: PROC is currently unprofitable.

Growing Profit Margin: PROC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PROC's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare PROC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PROC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: PROC has a negative Return on Equity (-124.29%), as it is currently unprofitable.


Financial Health

How is Procaps Group's financial position?


Financial Position Analysis

Short Term Liabilities: PROC's short term assets ($312.9M) exceed its short term liabilities ($276.7M).

Long Term Liabilities: PROC's short term assets ($312.9M) exceed its long term liabilities ($151.7M).


Debt to Equity History and Analysis

Debt Level: PROC's net debt to equity ratio (326.3%) is considered high.

Reducing Debt: Insufficient data to determine if PROC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable PROC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: PROC is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 74.1% per year.


Dividend

What is Procaps Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PROC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PROC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PROC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PROC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PROC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.2yrs

Average management tenure


CEO

Ruben Minski (69 yo)

46yrs

Tenure

Mr. Ruben Minski is Founded Procaps Group, S.A. in 1976 ant has been its Chief Executive Officer and serves as its Chairman. He received a Chemical Engineering degree from Northeastern University in Boston...


Leadership Team

Experienced Management: PROC's management team is seasoned and experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Procaps Group, S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Procaps Group, S.A.
  • Ticker: PROC
  • Exchange: NasdaqGM
  • Founded: 1977
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.030b
  • Shares outstanding: 112.82m
  • Website: https://www.procapsgroup.com

Number of Employees


Location

  • Procaps Group, S.A.
  • 9 rue de Bitbourg
  • Luxembourg City
  • 1273
  • Luxembourg

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 23:20
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.